HOTH News and Press, Hoth Therapeutics Inc. From 02/29/24

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company , today announced that it will continue its ...

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic PR Newswire Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb....

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 PR Newswire NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Of...

2024-01-18 09:57:45 ET More on Hoth Therapeutics Hoth stock jumps on positive FDA feedback on drug HT-KIT Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Seeking Alpha’s Quant Rating on Hoth Therapeutics Historical...

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients PR Newswire Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 ...

2023-12-27 10:00:36 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami PR Newswire NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical c...

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies PR Newswire NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical com...

2023-11-14 09:45:28 ET Hoth Therapeutics ( NASDAQ: HOTH ) stock jumped 6% in early trading after the company said it received positive feedback from the FDA on the proposed development plan for its oncology drug candidate HT-KIT. Hoth said in a statement that it met with the...

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT PR Newswire Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Ho...